

ACCEPTANCE REVIEW MEMO

Licensee: Benefis Healthcare dba Benefis Healthcare East
License No.: 25-12710-01 **Docket No.:** 030-02404
Mail Control No.: 470518
Type of Action: Amend **Date of Requested Action:** 04-05-05
Reviewer Assigned: Judith **Date Assigned to Reviewer:** 05-02-05
Reviewer(s) Who Performed Review: Torres - Walker

Response Received	Deficiencies Noted During Acceptance Review
1.	Need to submit NRC Form 313A to document Dr. Ro's experience in 35.300.
2.	<i>See fax dated 5/27/05</i>
3.	
4.	

Reviewer's Initials: *JW*

Date: *5/31/05*

Branch Chief's and/or SR. HP's Initials: *JAC*

Date: *5/31/05*

<input type="checkbox"/> Yes <input type="checkbox"/> No	Action - decommissioning notification should be issued within 30 days.
<input type="checkbox"/> Yes <input type="checkbox"/> No	Termination request < 90 days from date of expiration
<input type="checkbox"/> Yes <input type="checkbox"/> No	Action to be expedited
	<input type="checkbox"/> Medical emergency <input type="checkbox"/> Licensee in noncompliance (i.e. no RSO, location of use/storage not on license, radioactive material in possession not on license) <input type="checkbox"/> National Security <input type="checkbox"/> Other (_____)
Branch Chief's and/or Sr. HP's Initials: _____	
Date: _____	

SISP Review	
<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Non-Publicly Available, Sensitive if <u>any</u> item below is checked <input type="checkbox"/> Radionuclides, forms, and quantities <input type="checkbox"/> Location of RAM <input type="checkbox"/> Building drawings with locations of RAM <input type="checkbox"/> Security of RAM (locks, alarms, etc.) <input type="checkbox"/> SS&D Catalog information <input type="checkbox"/> Specifics of Emergency Plan (routes to and from RAM, response to security events, etc.) <input type="checkbox"/> Safeguards Information
Branch Chief's and/or Sr. HP's Initials: <u><i>JAC</i></u>	
Date: <u><i>5/21/05</i></u>	

facsimile
TRANSMITTAL

U.S. Nuclear Regulatory Commission
Region IV
611 Ryan Plaza Drive, Suite 400
Arlington, Texas 76011
DIVISION OF NUCLEAR MATERIALS SAFETY

Name: Kari Cann, RSO
Licensee: Benefis Healthcare

Phone: 406-455-2060
Fax: 406-455-2071


From: Judith Walker (817-860-8299) 817-860-8263 fax
Date: May 5, 2005
Subject: License Amendment
Pages: 5 (including cover)

Ms. Cann:

Concerning your license amendment request to add Dr. Ro as an authorized user, please submit NRC Form 313A to document experience in 35.300. You can fax your response back to 817-860-8263.

If you have questions regarding this fax, please contact me at 817-860-8299.

Sincerely,


Judith Walker
Health Physicist

TRAINING AND EXPERIENCE AND PRECEPTOR STATEMENT

PART I – TRAINING AND EXPERIENCE

Note: Descriptions of training and experience must contain sufficient detail to match the training and experience criteria in the applicable regulations.

1. Name of Individual, Proposed Authorization (e.g., Radiation Safety Officer), and Applicable Training Requirements (e.g., 10 CFR 35.50)

Noe Directive, MD Authorized user, 10 CFR 35.190, 10 CFR 35.290

2. For Physicians, Podiatrists, Dentists, Pharmacists – State or Territory Where Licensed

Pennsylvania Medical License PA-MD-XXYYY

3. CERTIFICATION

Specialty Board	Category	Month and Year Certified
N/A		

Stop here when using Board Certification to meet 10 CFR Part 35 training and experience requirements.

4. DIDACTIC OR CLASSROOM AND LABORATORY TRAINING (optional for Medical Physicists)

Description of Training	Location	Clock Hours	Dates of Training
Radiation Physics and Instrumentation	Radiation 200 for Diagnostic Physicians Sample Medical School 4321 Broad Street	50	July 1 to August 15, 2002
Radiation Protection	Anytown, PA	50	"
Mathematics Pertaining to the Use and Measurement of Radioactivity	"	50	"
Radiation Biology	"	50	"
Chemistry of Byproduct Material for Medical Use	"	50	"
OTHER			

470518

TRAINING AND EXPERIENCE AND PRECEPTOR STATEMENT (continued)

5a. WORK EXPERIENCE WITH RADIATION

Description of Experience	Name of Supervising Individual(s)	Location and Corresponding Materials License Number	Dates and Clock Hours of Experience
Ordering, receiving, and unpacking radioactive material safely and performing the related radiation surveys.	Thomas Group, D.O.	See item 9	August 2002 to March 2003 100
Calibrating instruments used to determine the activity of dosages and performing checks for proper operation of survey meters.	"	"	100
Calculating, measuring, and safely preparing patient or human research subject dosages	"	"	100
Using administrative controls to prevent a medical event involving the use of unsealed byproduct material	"	"	50
Using procedures to safely contain spilled radioactive material and using proper decontamination procedures.	"	"	50
Administering dosages of radioactive drugs to patients or human research subjects	"	"	100
Eluting generators, measuring and testing the eluate, and processing the eluate with reagent kits to prepare labeled radioactive drugs.	Jane Diagnostic, MD	See item 12	50
			Total > 700 hours

5b. SUPERVISED CLINICAL CASE EXPERIENCE - N/A

Radionuclide	Type of Use	No. of Cases Involving Personal Participation	Name of Supervising Individual	Location and Corresponding Materials License Number	Dates and Clock Hours of Experience
N/A					

TRAINING AND EXPERIENCE AND PRECEPTOR STATEMENT (continued)

6. FORMAL TRAINING (applies to Medical Physicists and Therapy Physicians)

Degree, Area of Study or Residency Program	Name of Program and Location with Corresponding Materials License Numbers	Dates	Name of Organization that Approved the Program (e.g., Accreditation Council for Graduate Medical Education) and the Applicable Regulation (e.g., 10 CFR 35.490)
N/A			

7. RADIATION SAFETY OFFICER – ONE-YEAR FULL-TIME TRAINING

- YES Completed 1-year of full-time radiation safety experience (in areas identified in item 5a) under supervision of
- N/A _____ the RSO for License No. _____.

8. MEDICAL PHYSICIST -- ONE YEAR FULL-TIME TRAINING/WORK EXPERIENCE

- YES Completed 1-year of full-time training in therapeutic radiological physics under the supervision of
- N/A _____ who meets requirements for Authorized Medical Physicists; and
- YES Completed 1-year of full-time work experience (for areas identified in item 5a) for _____
- N/A modality(ies) under the supervision of _____ who meets requirements for Authorized Medical Physicists for _____ modality(ies).

9. SUPERVISING INDIVIDUAL – IDENTIFICATION AND QUALIFICATIONS

The training and experience indicated above was obtained under the supervision of (if more than one supervising individual is needed to meet requirements in 10 CFR 35, provide the following information for each):

A. Name of Supervisor

Supervisor is:

Thomas Group, D.O.

- Authorized User
 Radiation Safety Officer

- Authorized Medical Physicists
 Authorized Nuclear Pharmacists

C. Supervisor meets requirements of Part 35, Section(s) **35.290**

for medical uses in Part 35, Section(s) **35.100 and 35.200**

D. Address

**Sample Medical-Institution Limited
1234 Main Street
Anytown, PA 02120**

E. Materials License Number

99-02120-01

TRAINING AND EXPERIENCE AND PRECEPTOR STATEMENT (continued)

PART II -- PRECEPTOR STATEMENT

Note: This part must be completed by the individual's preceptor. If more than one preceptor is necessary to document experience, obtain a separate preceptor statement from each. This part is not required to meet the training requirements in 10 CFR 35.590.

Item 10 must be completed for Nuclear Pharmacists meeting the requirements of 10 CFR Part 35, Subpart J. Preceptors do not have to complete items 11a, 11b, or the certifying statements for other individuals meeting the requirements of 10 CFR Part 35, Subpart J.

YES 10. The individual named in item 1 has satisfactorily completed the training requirements in
 N/A 10 CFR 35.980 and is competent to independently operate a nuclear pharmacy.

YES 11a. The individual named in Item 1 has satisfactorily completed the requirements in Part 35, Section(s) and
 N/A Paragraph(s) 35.190(c) and 35.290(c)

YES 11b. The individual named in Item 1. is competent to independently function as an authorized
 N/A User for 10 CFR 35.100 and 200 uses.

12. PRECEPTOR APPROVAL AND CERTIFICATION

I certify the approval of item 10 and certify I am an Authorized Nuclear Pharmacist;

OR

I certify the approval of items 11a and 11b, and certify I am an Authorized Nuclear Pharmacist;

OR

I certify the approval of Items 11a and 11b, and I certify that I meet the requirements of 35.290
or equivalent Agreement State requirements to be a preceptor authorized User
for the following uses of byproduct material: 35.100 and 35.200

A.. Address

**Sample Medical Institution Limited
1234 Main Street
Anytown, PA 02120**

B. Materials License Number

99-02120-01

C. NAME OF PRECEPTOR (print clearly)

Jane Diagnostic, MD

D. SIGNATURE -- PRECEPTOR

Jane Diagnostic

E. DATE

4-11-03

Kari Cann, MS DABR
Radiation Safety Officer

406-455-2059 (p)
406-455-2071 (F)

MAY 27 2005



Fax

To: Judith Walker **From:** Kari Cann, MS RSO

Fax: 817-860-8263 **Pages:** 5 4

Phone: 817-860-8299 **Date:** 5/27/2005

Re: Benefis Healthcare
NRC License 25-12710-01

- Urgent For Review Please Comment Please Reply Please Recycle
-

Hi Judith,

I have received notification from St Louis University the Dr. Ro does not have sufficient clinical experience for Part 300 type materials. We will obtain that experience here at Benefis and resubmit his credential at a later date.

100 + 200

Would you please pass this on to Jacqueline Cook regarding the Great Falls Clinic license number 25-27721-01? I left a voicemail for her on this subject today.

I would like to add Dr Carol Swartz, MD (aka Carol Swartz Milburn) to the Benefis Healthcare License (25-12710-01) as an authorized user for 10 CFR Part 35.400 materials. To that end, I am attaching NRC form 313a Part 1, a copy of her Board Certification in Therapeutic Radiology and evidence of continuing education in the last seven years.

Please contact me if there are any questions or concerns regarding this addition.

Thank you for you time in these matters,

Kari Cann, MS DABR
Medical Physicist / RSO
Benefis Healthcare

470518

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Nuclear Society, the American Society of North America
and the Section on Radiology of the American Medical Association

Carol Susan Milburn, M.B.

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology

On this sixth day of June, 1969

Thereby demonstrating to the satisfaction of the Board
that she is qualified to practice the specialty of
Therapeutic Radiology

John A. ... *A. ...*



EVIDENCE OF
CONTINUING EDUCATION
CAROL SWARTZ

Curriculum vitae
Carol J. Swartz, MD

Page 6
Update: dec 2003

CME category 1 credits 2003 88 hours
USF 20
Practical reviews in CA management 45
Pain management- 12
Brachytherapy-Prostate CA 11

CME category 1 credits 2002 74.75 hours
Johns Hopkins -practical reviews Ca mgt 30 hrs
Duke- ethics 6 hrs
APA -Risk mgt 2 hrs
USF 23 hrs
St Luke Hospitals -Pain Mgt-end of life 3 hrs
International Center-Management Prostate Ca 5.75 hrs

CME category 1 credits 2001 92 hours
Alcohol, Drugs and the Health Care Professional 3.5 hr UK
Aids 5 CME Research
Recent Advances in Prostate Ca 5.5 Med Education Collaborative
Lung Cancer 6 UC
Risk Management 2 APA
Ca A Journal prostate 1 CA Journal
Geriatric Patient 2 USF
Sarcoma 4 USF
Geriatric Cancer 1 USF
Prostate Cancer 4 USF
Cancer in the Elderly 4 USF
Lung Cancer 4 USF
Breast cancer 4 USF
Oncologic Support and Care 4 USF
Radioprotection 1 USF
Cancer Management 30 JOHNS HOPKINS
Cancer Management 15 Albert Einstein
Progress in Oncology 4 USF
Recent advances mgt prostate ca 5.75 ICPME

2000 66 Hrs
1999 110.5 Hrs

CME 2000 Category 1 hours 66
Risk Management 2 MICOA
Lung Ca 1 Phys Ed Resource
Prostate Ca 2 UK
Lung Ca 4 U So Florida
Ca Pain Mgt 4 U So Fl
Thyroid Ca 4 U So Fl
Bladder Ca 4 U So Fl
Pancreatic Ca 4 U So Fl
Practical Reviews Ca 36 Albert Einstein
Prostate Ca 1 ACS

NRC FORM 313A (10-2002)	U.S. NUCLEAR REGULATORY COMMISSION TRAINING AND EXPERIENCE AND PRECEPTOR STATEMENT	APPROVED BY OMB: NO. 3150-0120 EXPIRES: 10/31/2005	
PART I - TRAINING AND EXPERIENCE			
Note: Descriptions of training and experience must contain sufficient detail to match the training and experience criteria in the applicable regulations.			
1. Name of individual, Proposed Authorization (e.g., Radiation Safety Officer), and Applicable Training Requirements (e.g., 10 CFR 35.50) <p style="text-align: center; font-size: 1.2em;">CAROL SWARTZ, MD AUTHORIZED USER 10 CFR 35:</p>			
2. For Physicians, Podiatrists, Dentists, Pharmacists -- State or Territory Where Licensed <p style="text-align: center; font-size: 1.2em;">STATE OF MONTANA</p>			
3. CERTIFICATION			
Specialty Board	Category	Month and Year Certified	
AMERICAN BOARD OF RADIOLOGY	Therapeutic Radiology	June 1969	
<i>Stop here when using Board Certification to meet 10 CFR Part 35 training and experience requirements.</i>			
4. DIDACTIC OR CLASSROOM AND LABORATORY TRAINING (optional for Medical Physicists)			
Description of Training	Location	Clock Hours	Dates of Training
Radiation Physics and Instrumentation			
Radiation Protection			
Mathematics Pertaining to the Use and Measurement of Radioactivity			
Radiation Biology			
Chemistry of Byproduct Material for Medical Use			
OTHER			



United States Nuclear Regulatory Commission
Region IV
611 Ryan Plaza Drive, Suite 400
Arlington, Texas 76011-8064

APR 25 2005

April 5, 2005

SUBJECT: License amendment

This letter is to request a license amendment for changes to the Authorized Users for Benefis Healthcare, NRC License number 25-12710-01.

1. Please add the following individuals to the Authorized User list with the corresponding Material and Use authorization:

George Ro, MD for material identified in 10 CFR 35.100, 35.200, 35.300,

I have attached a copy of Dr. Ro's ABR certification in Diagnostic Radiology and a letter attesting to his training and qualification for 10 CFR 35.300.

Thomas Borok, MD for material identified in 10 CFR 35.400

I have attached a copy of Dr. Borok's ABR certification in Therapeutic Radiology. I have also included a copy of his CME's demonstrating continuing education in the last 7 years.

Hiebert Vriesendorp, MD for material identified in 10 CFR 35.400

I have attached a copy of Dr. Vriesendorp's ABR certification in Therapeutic Radiology. I have also included a copy of his CV demonstrating continuing education and experience in the field of Radiation Oncology in the last 7 years.

2. Please remove the following individual from the Authorized users list:

Robert Pfeffer, MD for material identified in 10 CFR 35.400

The above changes were reviewed and approved by the Benefis Healthcare Radiation Safety Committee at the regularly scheduled meeting on March 7, 2005 and via telephone conference with committee members on April 5, 2005.

Thank you for your attention to this matter. Please contact Kari Cann, MS our Radiation Safety Officer at 406-455-2060 if you have any questions. 406-455-2071 (fax)

Sincerely,

John Goodnow
President and CEO

Attachments

Kari Cann, MS DABR
Radiation Safety Officer

406-455-2059 (p)
406-455-2071 (F)

MAY 27 2005



Fax

To: Judith Walker **From:** Kari Cann, MS RSO
Fax: 817-860-8263 **Pages:** 3 4
Phone: 817-860-8299 **Date:** 5/27/2005
Re: Benefis Healthcare
NRC License 25-12710-01

Urgent For Review Please Comment Please Reply Please Recycle

Hi Judith,

I have received notification from St Louis University the Dr. Ro does not have sufficient clinical experience for Part 300 type materials. We will obtain that experience here at Benefis and resubmit his credential at a later date.

Would you please pass this on to Jacqueline Cook regarding the Great Falls Clinic license number 25-27721-01? I left a voicemail for her on this subject today.

I would like to add Dr Carol Swartz, MD (aka Carol Swartz Milburn) to the Benefis Healthcare License (25-12710-01) as an authorized user for 10 CFR Part 35.400 materials. To that end, I am attaching NRC form 313a Part 1, a copy of her Board Certification in Therapeutic Radiology and evidence of continuing education in the last seven years.

Please contact me if there are any questions or concerns regarding this addition.

Thank you for you time in these matters,

Kari Cann, MS DABR
Medical Physicist / RSO
Benefis Healthcare

05/27/2005

NRC FORM 313A (10-2002)	U.S. NUCLEAR REGULATORY COMMISSION	APPROVED BY OMB: NO. 3150-0120 EXPIRES: 10/31/2005	
TRAINING AND EXPERIENCE AND PRECEPTOR STATEMENT			
PART I - TRAINING AND EXPERIENCE			
<p>Note: Descriptions of training and experience must contain sufficient detail to match the training and experience criteria in the applicable regulations.</p>			
1. Name of Individual, Proposed Authorization (e.g., Radiation Safety Officer), and Applicable Training Requirements (e.g., 10 CFR 35.50) <p style="text-align: center; font-size: 1.2em;">CAROL SWARTZ, MD AUTHORIZED USER 10 CFR 35:</p>			
2. For Physicians, Podiatrists, Dentists, Pharmacists -- State or Territory Where Licensed <p style="text-align: center; font-size: 1.2em;">STATE OF MONTANA</p>			
3. CERTIFICATION			
Specialty Board	Category	Month and Year Certified	
AMERICAN BOARD OF RADIOLOGY	Therapeutic Radiology	June 1969	
<i>Stop here when using Board Certification to meet 10 CFR Part 35 training and experience requirements.</i>			
4. DIDACTIC OR CLASSROOM AND LABORATORY TRAINING (optional for Medical Physicists)			
Description of Training	Location	Clock Hours	Dates of Training
Radiation Physics and Instrumentation			
Radiation Protection			
Mathematics Pertaining to the Use and Measurement of Radioactivity			
Radiation Biology			
Chemistry of Byproduct Material for Medical Use			
OTHER			

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Nuclear Society, the American Society of North America
and the Section on Radiology of the American Medical Association

Carol Susan Wilburn, M.D.

Has pursued an accepted course of graduate study
and clinical work has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology

On this sixth day of June, 1969

Thereby demonstrating to the satisfaction of the Board
that she is qualified to practice the specialty of
Therapeutic Radiology

John C. ... *A. ...*



EVIDENCE OF
CONTINUING EDUCATION
CAROL SWARTZ

Curriculum vitae
Carol J. Swartz, MD
Page 6
Update: dec 2003

MAY 27 2005

CME category 1 credits 2003 **88 hours**
USF **20**
Practical reviews in CA management **45**
Pain management- **12**
Brachytherapy-Prostate CA **11**


CME category 1 credits 2002 **74.75 hours**
Johns Hopkins -practical reviews Ca mgt **30 hrs**
Duke- ethics **6 hrs**
APA -Risk mgt **2 hrs**
USF **28 hrs**
St Luke Hospitals -Pain Mgt-end of life **3 hrs**
International Center-Management Prostate Ca **5.75 hrs**

CME category 1 credits 2001 **92 hours**
Alcohol, Drugs and the Health Care Professional **3.5 hr UK**
Aids **5 CME Research**
Recent Advances in Prostate Ca **5.5 Med Education Collaborative**
Lung Cancer **6 UC**
Risk Management **2 APA**
Ca A Journal prostate **1 CA Journal**
Geriatric Patient **2 USF**
Sarcoma **4 USF**
Geriatric Cancer **1 USF**
Prostate Cancer **4 USF**
Cancer in the Elderly **4 USF**
Lung Cancer **4 USF**
Breast cancer **4 USF**
Oncologic Support and Care **4 USF**
Radioprotection **1 USF**
Cancer Management **30 JOHNS HOPKINS**
Cancer Management **15 Albert Einstein**
Progress in Oncology **4 USF**
Recent advances mgt prostate ca **5.75 ICPME**

2000 **66 Hrs**
1999 **110.5 Hrs**

CME 2000 Category 1 hours **66**
Risk Management **2 MICOA**
Lung Ca **1 Phys Ed Resource**
Prostate Ca **2 UK**
Lung Ca **4 U So Florida**
Ca Pain Mgt **4 U So Fl**
Thyroid Ca **4 U So Fl**
Bladder Ca **4 U So Fl**
Pancreatic Ca **4 U So Fl**
Practical Reviews Ca **36 Albert Einstein**
Prostate Ca **1 ACS**

470518



3635 Vista Ave. at Grand Blvd.
P.O. Box 15250
St. Louis, MO 63110-0250
Phone: 314-268-5780
FAX: 314-268-5116

**SAINT LOUIS
UNIVERSITY**

**Health Sciences Center
School of Medicine**

Department of Radiology

**Michael K. Wolverson, M.D.
Professor and Chairman**

April 8, 2005

Benefits Healthcare
Great Falls MT 59401

To Whom It May Concern:

I certify that Dr. George Ro has received the following training and experience at our institution, St. Louis University Hospital, under the supervision of an authorized user. Our radioactive material license number is 24-00196-07

The training satisfies all aspects of the following US Nuclear Regulatory Commission requirement:

§35.390 Training for use of unsealed byproduct material for which a written directive is required

Except as provided in § 35.57, the licensee shall require an authorized user of unsealed byproduct material for the uses authorized under § 35.300 to be a physician who--

(a) Is certified by a medical specialty board whose certification process includes all of the requirements in paragraph (b) of this section and whose certification has been recognized by the Commission or an Agreement State; or (b)(1) Has completed 700 hours of training and experience in basic radionuclide handling techniques applicable to the medical use of unsealed byproduct material requiring a written directive. The training and experience must include--

(i) Classroom and laboratory training in the following areas--

(A) Radiation physics and instrumentation;

(B) Radiation protection;

(C) Mathematics pertaining to the use and measurement of radioactivity;

(D) Chemistry of byproduct material for medical use; and

(E) Radiation biology; and

(ii) Work experience, under the supervision of an authorized user who meets the requirements in § 35.390(a), § 35.390(b), or equivalent Agreement State requirements. A supervising authorized user, who meets the requirements in § 35.390(b), must have experience in administering dosages in the same dosage category or categories (i.e., § 35.390(b)(1)(ii)(G)(1), (2), (3), or (4)) as the individual requesting authorized user status. The work experience must involve--

(A) Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;

(B) Calibrating instruments used to determine the activity of dosages, and performing checks for proper operation of survey meters;

(C) Calculating, measuring, and safely preparing patient or human research subject dosages;

(D) Using administrative controls to prevent a medical event involving the use of unsealed byproduct material;

(E) Using procedures to contain spilled byproduct material safely and using proper decontamination procedures;

(F) Eluting generator systems, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs; and

(G) Administering dosages of radioactive drugs to patients or human research subjects involving a minimum of three cases in each of the following categories for which the individual is requesting authorized user status--

(1) Oral administration of less than or equal to 1.22 Gigabecquerels (33 millicuries) of sodium iodide I-131;

(2) Oral administration of greater than 1.22 Gigabecquerels (33 millicuries) of sodium iodide I-131;

2 Experience with at least 3 cases in Category (G)(2) also satisfies the requirement in Category (G)(1).

(3) Parenteral administration of any beta emitter or a photon-emitting radionuclide with a photon energy less than 150 keV; and/or

(4) Parenteral administration of any other radionuclide; and

(2) Has obtained written certification that the individual has satisfactorily completed the requirements in paragraph (b)(1) of this section and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under § 35.300. The written certification must be signed by a preceptor authorized user who meets the requirements in § 35.390(a), § 35.390(b), or equivalent Agreement State requirements. The preceptor authorized user, who meets the requirements in § 35.390(b), must have experience in administering dosages in the same dosage category or categories (i.e., § 35.390(b)(1)(ii)(G)(1), (2), (3), or (4)) as the individual requesting authorized user status.



4-8-05

Signature of residency program director

Michael K. Wolverson, M.D.
Residency Program Director
Saint Louis University Hospital

1001 001

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine

Hereby certifies that

George Ra, MD

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of

The American Board of Radiology

On this eighth day of November, 2004

Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Diagnostic Radiology



Certificate No. 51143

Thomas A. Feicht, M.D.
President

Richard T. Hoppe, MD
Secretary-Treasurer

R.P. Hickey, MD
Executive Director



Valid through 2014

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association
and the American Society of Therapeutic Radiologists

Hereby certifies that

Thomas Louis Borok, M.D.

Had pursued an accepted course of graduate study
and clinical work, had met certain standards and qualifications and
had passed the examinations conducted under the authority of

The American Board of Radiology

On this fifth day of June, 1981

Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Therapeutic Radiology



Herald B. Greenberg, M.D.
President

James L. Zalkow, M.D.
Secretary



The University of Texas System Cancer Center
M.D. Anderson Hospital and Tumor Institute
Houston, Texas





Thomas L. Borok, M.D.

has successfully completed

Fellowship in Radiotherapy

July 1, 1980 to June 30, 1981


DEPARTMENT HEAD


PRESIDENT

Thomas Louis Borok, M.D. 2005 CME category 1:

institution/sponser	accreditation type		date	hours
MediCom Worldwide		mail in	emerging solutions in pain volume 3 #1	3/1/2005 1
American Cancer Society	ACCME	mail in	cancer statistics 2004 CA journal vol 54 #1	3/2/2005 1.5
American Cancer Society	ACCME	mail in	cancer disparities race ethnicity socioeconomic class/sarcomas, alternati	3/31/2005 2
American Cancer Society	ACCME	mail in	evidence based staging system for cutaneous melanoma	3/31/2005 1
Physicians Education Resource	ACCME	mail in	advances antibody mediated therapy lymphoma	1/1/2005 0.5
Physicians Education Resource	ACCME	mail in	human epidermal growth factors in oncology	1/1/2005 1
Physicians Education Resource	ACCME	mail in	multitargeted antifolate mesothelioma, lung cancer	1/1/2005 0.5
Wolters Kluwer Health American HeartAssociation	ACCME	mail in	coronary artery disease	1/1/2005 2
American Academy of CME	ACCME	mail in	epidermal growth factor inhibition NSCLC and Head&Neck	1/1/2005 2
University South Florida	ACCME	mail in	stem cell transplantation cancer control vol 11 #2	1/1/2005 4
Texas A&M University Health Science Center	ACCME	mail in	Christus Spohn Shoreline Hospital Tumor Conference	1/5/2005 1
American Academy of CME	ACCME	mail in	evedence based medicine and brain metastasis	3/1/2005 2.5
Physicians Education Resource	ACCME	mail in	biologic therapy of cancer volume 2 # 1	3/2/2005 1
American Academy CME	ACCME	mail in	thoracic & head and Neck malignancy	3/3/2005 2.25
Center for Biomedical Continuing Education	ACCME	mail in	epidermal growth factor inhibitors NSCLC	3/4/2005 3
University South Florida	ACCME	mail in	constipation cancer control volume 11 # 3 suppliment	3/5/2005 2
Physicians Education Resource	ACCME	mail in	case studies in breast cancer volume 3 # 6	3/6/2005 1
Physicians Education Resource	ACCME	mail in	biological therapy breast cancer vol 5 # 1	3/7/2005 1
Physicians Education Resource	ACCME	mail in	biological therapy lymphoma vol 7 # 2	3/8/2005 1
Physicians Education Resource	ACCME	mail in	vascular endothelial growth factor in oncology vol 1 # 1	3/9/2005 1
University South Florida	ACCME	mail in	skull base tumors, growth factors cancer control vol 11 #3	3/10/2004 4
American Cancer Society	ACCME	mail in	complications pediatric cancer CA journal vol 54 #4	3/11/2005 1.5 vs. 1 hr.
Physicians Education Resource	ACCME	mail in	case studies in breast cancer vol 3 # 8	3/12/2005 1
Physicians Education Resource	ACCME	mail in	case studies in lung cancer vol 3 # 5	3/13/2005 1
Physicians Education Resource	ACCME	mail in	case studies in colorectal cancer vol 3 # 2	3/14/2005 1
Physicians Education Resource	ACCME	mail in	case studies in breast cancer vol 3 # 11	3/15/2005 1
Physicians Education Resource	ACCME	mail in	cancer abstracts & summaries vol 5 # 7	3/16/2005 1
Physicians Education Resource	ACCME	mail in	monographs in lymphoma vol 5 # 1	3/17/2005 1
University South Florida	ACCME	mail in	breast cancer cancer control vol 11 # 4	3/18/2005 4
University South Florida	ACCME	mail in	ocular tumors cancer control vol 11 # 5	3/19/2005 4
American Cancer Society	ACCME	mail in	HPV patient education CA journal vol 54 # 5	3/20/2005 1.5
Physicians Education Resource	ACCME	mail in	Case Studies Colorectal Cancer vol 3 #3	3/21/2005 1
Physicians Education Resource	ACCME	mail in	Case Studies Colorectal Cancer vol 3 #4	3/22/2005 1
Physicians Education Resource	ACCME	mail in	vascular endothelial growth factor in oncology vol 1 # 2	3/23/2005 1
Physicians Education Resource	ACCME	mail in	vascular endothelial growth factor in oncology vol 1 # 3	3/24/2005 1
Physicians Education Resource	ACCME	mail in	vascular endothelial growth factor in oncology vol 1 # 4	3/25/2005 1
Physicians Education Resource	ACCME	mail in	evolving treatment paradigms lymphoma update ASCO 2004	3/26/2005 1
American Academy CME	ACCME	mail in	whole brain radiotherapy brain metastasis	3/27/2005 2.5
American Academy CME	ACCME	mail in	EGFR targeted therapy squamous carcinoma head and neck	3/28/2005 1.75
American Academy CME	ACCME	mail in	EGFR targeted therapy current treatment non small cell lung cancer	3/29/2005 1.75
American Cancer Society	ACCME	mail in	colorectal cancer screening CA journal vol 54 #6	3/30/2005 1
American Cancer Society	ACCME	web	cancer statistics 2005 CA journal vol 55 #1	3/31/2005 1.5
Physicians Education Resource	ACCME	mail in	monographs in lymphoma vol 5 # 2	4/1/2005 1
Physicians Education Resource	ACCME	mail in	biological therapy of breast cancer vol 5 # 2	4/2/2005 1
Benefis Healthcare Education Services		confere	tumor conference case presentation	4/8/2005 1
Benefis Healthcare Education Services		confere	tumor conference case presentation	4/15/2005 1

2005 category 1 TOTAL

69.75

Thomas Louis Borok, M.D. 2005 CME category 2:

institution	place	title	date	hours
US Oncology Mesquite Texas	Cancer Center	Advances Treatment Early Breast Cancer	Stephen Jones MD	1/4/2005 1

2005 category 2 TOTAL

2005 TOTAL category 1 and 2

Thomas Louis Borok, M.D. 2004 CME category 1:

institution/sponser	accreditation	type	topic	date	hours
American Cancer Society	ACCME	mail in	CA cancer Journal for Clinicians Vol53#2 tobacco control	1/1/2004	2
University South Florida	ACCME	mail in	Cancer Control Vol10#2 gliomas, MRI,molecular therapy,MDR	1/1/2004	4
CME Consultants	ACCME	mail in	penetrating insights crossing cancer cell membrane	1/1/2004	2
University Florida	ACCME	mail in	new options antimicrobial therapy cancer marrow transplant	1/2/2004	2
Oxford Institute	ACCME	mail in	current approaches novel paradigms breast cancer therapy	1/3/2004	2
Coastal Bend Health Center	TxMedAssoc	conference	Christus Spohn tumor conference-multiple myeloma Dr. Alexanian	1/28/2004	1
American Cancer Society	ACCME	mail in	ongoing care after cancer treatment/breast cancer screening CAvol53;	3/1/2004	2
University South Florida	ACCME	mail in	Cancer Control Vol10#3 colorectal pancreatic cancer	3/2/2004	4
American Academy of CME	ACCME	Seton Hall U	combined modality therapy NSCLC and head and neck cancer	3/3/2004	1.5
University South Florida	ACCME	mail in	Cancer Control Vol10#4 Thoracic Oncology	3/4/2004	4
American Cancer Society	ACCME	mail in	Cancer Statistics, Elderly Breast, Agent Orange CAvol53#4	3/5/2004	2
MediCom Worldwide, Inc.	ACCME	mail in	Assessing Managing Low Back Pain option for opioids	3/6/2004	1
American Cancer Society	ACCME	mail in	CA cancer Journal for Clinicians Vol53#5 nutrition/physical activity	3/7/2004	2
American Cancer Society	ACCME	mail in	CA cancer Journal for Clinicians Vol53#6 breast cancer trends, cancer	3/8/2004	2
University South Florida	ACCME	mail in	Cancer Control Vol10#5 multiple myeloma	3/9/2004	4
University South Florida	ACCME	mail in	Cancer Control Vol10#6 geriatric oncology	3/4/2004	4
Texas Medical Association	ACCME	mail in	Ethics - Pain Control	3/1/2004	1
Texas Medical Association	ACCME	mail in	Ethics - Physician Retirement	3/1/2004	1
Coastal Bend Health Center	TxMedAssoc	conference	Christus Spohn tumor conference-breast cancer - unusual histologies	2/18/2004	1
Coastal Bend Health Center	TxMedAssoc	conference	Christus Spohn tumor conference-PNET/seminoma/merkle cell carcin	2/25/2004	1
University South Florida	ACCME	mail in	Cancer Control Vol 11#1 pancreas cancer	3/2/2004	4
Coastal Bend Health Center	TxMedAssoc	conference	Christus Spohn tumor conference-ependymoma, breast, penis carcin	2/25/2004	1
Baylor Hospital Irving		conference	cancer case presentation	3/16/2004	1
Institute Continuing Healthcare	ACCME	conference	radioimmunotherapy non-hodgkin's lymphoma	3/17/2004	1
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn tumor conference	3/31/2004	1
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn tumor conference chemotherapy dose intensity	4/14/2004	1
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn leukemia Dr. Hagop Kantargian	4/28/2004	1
U Texas SW Dallas	ACCME	conference	breast cancer journal club - mammosite	5/20/2004	2
U Texas SW Dallas	ACCME	conference	molecular profiling breast cancer	5/26/2004	2
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn tumor conference	6/16/2004	1
U Texas SW Medical Center	ACCE	conference	ASCO 2004 update	6/24/2004	2
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn tumor conference	6/30/2004	1
CME Consultants	TMA	conference	Christus Spohn - treatment update non small cell lung cancer	8/18/2004	1
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn tumor conference - deep vein thrombosis	9/1/2004	1
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn tumor conference - colorectal cancer angiogenesis int	9/15/2004	1
U Texas SW Dallas	ACCME	conference	GI Cancer Roundtable	11/9/2004	2
U North Texas Health Science	ACCME	conference	recent updates non small cell lung cancer	11/18/2004	1
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn tumor conference	12/1/2004	1
CoastalBendHealthEdCenter	TMA	conference	Christus Spohn tumor conference	12/15/2004	1

2004 category 1 TOTAL

69.5

Thomas Louis Borok, M.D. 2004 CME category 2:

institution	place	title	date	hours
International Journal Radiation Oncology	journal			
Seminars Radiation Oncology	journal			
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	1/26/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	1/27/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	1/28/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	1/29/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	1/30/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/16/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/17/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/18/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/19/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/20/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/23/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/24/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/25/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/26/2004	1
Radiation Oncology Rounds	Christus Spohn Hospital	Patient Case Management and peer review with Dr. Daniel Garlitos	2/27/2004	1
Bexxar Radiotherapy CD20 +		Bexxar Radiotherapy monoclonal antibody dosing-refractory lymphom	2/23/2004	1

2004 category 2 TOTAL

2004 TOTAL category 1 and 2

Thomas Louis Borok, M.D. 2003 CME category 1:

institution/sponsor	accreditation	type	title	date	hours
American Cancer Society	ACCME	mail in	ACS guidelines cancer prevention CA CancerJ for CliniciansVol52#	1/1/03	2
University South Florida Moffitt Cancer Center	ACCME	mail in	monoclonal Cancer Control Vol9#2	1/2/03	4
American Cancer Society	ACCME	mail in	hormonal therapy prostate CA Cancer Journal for Clinicians Vol52#:	3/13/03	2
Lippincott Williams & Wilkins	ACCME	mail in	medical administration, office systems, medical management	3/24/03	2
American Cancer Society	ACCME	mail in	oral cancer/ovary cancer CA Cancer Journal for Clinicians Vol52#4	3/13/03	1.5
Postgraduate Institute for Medicine	ACCME	mail in	new advances oral alkylating agents CNS malignancy	3/4/03	1
University South Florida Moffitt Cancer Center	ACCME	mail in	colony stim factor, hypopituitarism, acromegaly Cancer Control 9#3	3/30/03	4
Dannemiller Memorial Educational Foundation		mail in	Issues In Radiation Therapy: Lung Cancer	3/10/03	1.5
University South Florida Moffitt Cancer Center	ACCME	mail in	urologic cancer Cancer Control Vol9#4	3/30/03	4
American Cancer Society	ACCME	mail in	breast cancer 2002 CA Cancer Journal For Clinicians Vol52#5	3/13/03	2.5
University South Florida Moffitt Cancer Center	ACCME	mail in	head and neck cancer Cancer Control vol 9 # 5	3/30/03	4
American Cancer Society	ACCME	mail in	ACS guidelines early detection cervix cancer CA Cancer J Vol52#6	3/13/03	1.5
University South Florida Moffitt Cancer Center	ACCME	mail in	Cancer Control vol 9#6 breast cancer	3/30/03	4
Memorial Hospital South Bend	IndStMedSoc	conference	Breast Cancer Forum 3 cases Drs. Borok, Zon, Friend, et al	1/2/03	1
Network for Continuing Medical Education	ACCME	conference	mixed dyslipidemia: multiple therapeutic targets;controlling atherosc	1/29/03	2
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Conference	2/7/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Bipolar Disorders	2/14/03	1
Texas Medical Society	ACCME	mail in	Nicotine Dependence and treatment - ETHICS	3/5/03	1
American Cancer Society	ACCME	mail in	Cancer Statistics CA Cancer J for Clinicians Vol 53 # 1	3/13/03	1.5
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Conference	3/7/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Conference	3/20/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Orthopedic Injuries	3/21/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Dermatology	3/28/03	1
University South Florida Moffitt Cancer Center	ACCME	mail in	Cancer Control vol 10#1 hematopoetic stem cells	3/28/03	4
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	allergy update	4/11/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Conference	4/17/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Conference	5/2/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Conscious Sedation	5/30/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Conference	7/17/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Total Parenteral Nutrition	7/11/03	1
American Academy of CME	Seton Hall U	mail in	chemoradioprotection in lung cancer	7/16/03	2
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	controlled substance prescribing	8/1/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Conference	10/2/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Pain Management in the Elderly Patient	10/3/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Conference	10/16/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Lung Cancer Chemotherapy	10/17/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Blastomycosis	10/31/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Tumor Board	11/6/03	1
St. Mary's Hospital Rhinelander Wisconsin	NIIMedSociet	conference	Neurorecepto Basis Anti-depressant choice	11/7/03	1

2003 category 1 TOTAL	65.5
-----------------------	------

Thomas Louis Borok, M.D. 2003 CME category 2:

institution	place	title	date	hours
International Journal Radiation Oncology Biol Phys	journal			15
Seminars Radiation Oncology	journal			20
International Journal Radiation Oncology	AMA	publish publication in peer review journal vol 56 #4 2003	3/1/03	2

2003 category 2 TOTAL	37
-----------------------	----

2003 TOTAL category 1 and 2	103
-----------------------------	-----

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association
and the American Society of Therapeutic Radiologists
Hereby certifies that

Hulbert Michiel Briesendorf, M.D.

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology

On this sixth day of June, 1985

Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Therapeutic Radiology



Arthur W. Brady, M.D.
President

Frank L. Zink, M.D.
Secretary



04/12/2005 12:09 8013040991

MEDICAL DOCTOR ASSOC

PAGE 02

Page 1 **H. M. VRIESENDORP, M.D., Ph.D.**
4/11/2005

CURRICULUM VITAE

Name Huibert Michiel Vriesendorp

Social Security Number

Address

Personal and Family

Date of Birth:

Place of Birth:

Marital Status:

Wife's Name:

Year of Marriage:

Children:

Nationality:

Educational and Academic Experience

1957-63	B.S., Gymnasium Beta, Praedinius Gymnasium, Groningen, The Netherlands
1963-68	M.D., Rijks Universiteit Leiden, The Netherlands
1968-71	Internships, Medical School, Erasmus Universiteit, Rotterdam, The Netherlands
1969-73	Immunogenetics (Ph.D. on Major Histocompatibility Complex of the Dog, 1973) Erasmus Medical School, Rotterdam, The Netherlands
1971-72	Primate Center GP-TNO, Rijswijk, The Netherlands

04/12/2005 12:13 8013040991

MEDICAL DOCTOR ASSOC

PAGE 02

**Page 2 H. M. VRIESENDORP, M.D., Ph.D.
4/11/2005**

1972-76	Radiobiological Institute GO-TNO, (Bone Marrow Transplantation, Donor Selection, and Total Body Irradiation in Dogs, Mice and Rhesus Monkeys) Rijswijk, The Netherlands
1976 March-August	Resident, Medicine Service, Zuider Ziekenhuis, Rotterdam, The Netherlands
1976-77 August-August	Fellow Hematologic Support Service Rotterdam Radiotherapeutic Institute, Rotterdam, The Netherlands
1977-78 Sept-Sept	Fellow, Clinical Oncology, Sidney Farber Cancer Institute, Boston, Massachusetts
1978-80 Sept-Sept	Radiobiological Research, Radiobiological Institute GO TNO, Ryswyk, The Netherlands
1982-84 Sept-Sept	Resident, Radiation Therapy, Northwestern University Chicago, Illinois
1987-90	Armed Forces Radiobiology Research Institute; July-July Bethesda, Maryland Visiting Scientist

Academic Appointments

1980-1982 Sept-Sept	Associate Professor of Medicine (Clinical Cancer Chemotherapy, Clinical Bone Marrow Transplantation, Purification of Bone Marrow Cells) (Leave of Absence 9/82) Northwestern University, Chicago, Illinois
1984-1990 Sept-Sept	Assistant Professor of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
1991-1996 Sept- Sept	Associate Professor of Radiation Therapy, The University of Texas, M. D. Anderson Cancer Center, Houston Texas.
1996-1998 Sept - Sept	Radiation Oncologist, Arlington Cancer Center Arlington, Texas
1998-1999 Sept - Dec	Consultant in Radiation Oncology and Radiolabeled Immunoglobulin Therapy, Paris France; Morgantown West Virginia; Chicago Illinois; Hanford Washington, London England, Groningen The Netherlands
2000-2001 Jan- Feb	Associate Physician, Radiation Oncologist Marshfield Clinic, Wisconsin
2001-2002	Locum tenens radiation oncologist in Illinois March- Sept [Zion], Colorado [Denver], Wisconsin [Janesville, Madison], Minnesota [VA Minneapolis] New York [Cooperstown, Latham]

04/12/2005 12:09

8013840991

MEDICAL DOCTOR ASSOC

PAGE 03

**Page 3 H. M. VRISENDORP, M.D., Ph.D.
4/11/2005**

2002 Oct- Nov	Virginia Mason Clinic Seattle, WA, radiation oncologist, locum tenens.
2003	Locum tenens radiation oncologist in Texas [Baytown, Harlingen, Odessa, Palestine, Austin]
2004 Jan-present	Clinical Professor Radiation Oncology New York University, NY
2004 March-April	Radiation Oncologist SUNY, Upstate Medical University Syracuse, NY
2004	Locum tenens radiation oncologist Texas [San Antonio] and Wisconsin [Rhinelander]
2005	Locum tenens radiation oncologist Texas [Midland]

Certification

1971	License to Practice Medicine, The Netherlands
1975	ECFMG (Examination of the Education Council for Foreign Medical Graduates) #249-401-1
1980	Radiation Protection (Level 3) Dutch Diploma
1980	Board Certification in Immunology (Dutch)
1980	FLEX (Federal Licensure Examination)
1980	License to Practice Medicine - State of Illinois # 036-061681
1981	VQE (Visa Qualifying Exam)
1984	License to Practice Medicine - State of Maryland #D31341, inactive, expired
1985	Board Certification in Therapeutic Radiology (American Board of Radiology)
1990	Board Certification in Therapeutic Radiology (Dutch Registry for Medical Specialists)
1991	License to Practice Medicine - State of Texas #J0717
1998	License to Practice Medicine - State of West Virginia #19724, inactive, expired
1999	License to Practice Medicine - State of Colorado #37695
1999	License to Practice Medicine - State of Washington #025209
1999	License to Practice Medicine - State of Wisconsin

04/12/2005 12:13

8013040991

MEDICAL DOCTOR ASSOC

PAGE 03

**Page 4 H. M. VRIESENDORP, M.D., Ph.D.
4/11/2005**

#41854-020

2001	Voluntary re-certification Radiation Oncology by American Board of Radiology
2001	License to Practice Medicine - State of New York #223451-1
2001	License to Practice Medicine - State of Montana #9975, inactive, expired 03/2004

Membership in Professional Societies

1973-present	International Society of Experimental Hematology
1978-80	International Society of Animal Blood Group Research
1975-80	Dutch Society for Immunology
1975-80	Dutch Society for Radiobiology
1975-80	Dutch Society for Medical Research Scientists (Board Member 1976-79)
1980-1995	American Society of Hematology
1983-present	American Society for Therapeutic Radiology and Oncology
1984-1994	Transplantation Society
1984-1995	Radiological Society of North America
1984-present	American Association for the Advancement of Science
1986-1992	American Society of Clinical Oncology
1986-1995	American Medical Association
1986-1995	New York Academy of Sciences
1988-present	Radiation Research Society
1991-1997	Gilbert Fletcher Society

Honors

1972	Biennial Prize of "Klinisch Genootschap Rotterdam" for Research Activities
1977	International John Fogarty Fellowship
1988	ESTRO-ASTRO Travel Fellowship
1996	Royal Society of Medicine, England, Burroughs Wellcome Visiting Professor

04/12/2005 12:05 0013040991

MEDICAL DOCTOR ASSOC

PAGE 04

Page 5 **H. M. VRIESENDORP, M.D., Ph.D.**
4/11/2005

2004

Member Nuclear Radiologic Response Task Force ASTRO

Editorial/Review Appointments

1973-1990

Assistant Editor, Tissue Antigens, Journal of
Histocompatibility and Immunogenetics

1982-2003

Ad hoc site visits NIH, study group Clinical
Oncology NCI {2000}, Grant evaluations European
Community for Radiation Oncology and
Biotechnology**Grant Support for the Past Ten Years****Industry**

1994 Hybritech

\$ 50,000

Donations

1994 H.Swyen

\$ 50,000

1995 Arlington

\$ 20,000

Extramural1997 North Texas Cancer Research \$ 50,000
Foundation

1999 Thomas Hodgkin's Foundation \$ 10,000

Patents

1. Radiolabeled IgM for intra-compartmental Therapy, pending for US, Canada, Europe and Japan. Co-inventor: Syed M Quadri, PhD, Sponsor: IQ Corporation, Groningen The Netherlands
2. Immune-Complex administrations for humoral autoimmunity, pending. Inventors: Vriesendorp, Groen, Lageveen.

Consultant

1. Chimeric Therapies Inc. 28202 Cabot Road, suite 210, Laguna Niguel Ca, 92677
2. Human Genome Sciences, Inc 9410 Key West Avenue, Rockville, MD 20850
3. Crucell, Archimedesweg 4, PO Box 2048, 2301 CA Leiden the Netherlands
4. IQ Corporation, Zernikepark 6E, 9747 AN Groningen, The Netherlands
5. NEXTherapeutics c/o Genetix Pharma 840 Memorial Drive Cambridge MA 02139

Page 6 **H. M. VRIESENDORP, M.D., Ph.D.**
4/11/2005

Articles Published in Professional Journals (over 145)

1. Wood, M.L. and Vriesendorp, H.M. A Comparative Study of Heterologous Anti-mouse Lymphocyte and Anti-mouse Thymocyte Sera Prepared by Two Different Immunization Methods. *Transplantation* 7:522-533; 1969.
2. Westbroek, D.L., Rothengatter, C., Vriesendorp, H.M., and van Rood, J.J., Histocompatibility and Heterotopic Segmental Small Bowel Allograft Survival in Dogs. *Eur.Surg. Res.* 2:401; 1970.
3. Bos, E., Meeter, K., Stibbe, J., Vriesendorp, H.M., Westbroek, D.L., de Vries, M.J., Nauta, J., and van Rood, J.J. Histocompatibility in Orthotopic Heart Transplantation in Dogs. *Transplant. Proc.* 3: 155-156; 1971.
4. Westbroek, D.L., Rothengatter, C., Vriesendorp, H.M., van Rood, J.J., Willighagen, R.G.J., and de Vries, M.J. Histocompatibility and Allograft Rejection in Canine Small Bowel Transplants. Evidence for the Existence of a Major Histocompatibility Locus in the Dog. *Transplant. Proc.* 3:157-160; 1971.
5. Vriesendorp, H.M., Rothengatter, C., Bos, E., Westbroek, D. L., van Rood, J.J. The production and evaluation of dog allolymphocytotoxins for donor selection in transplantation experiments. *Transplantation* 11 :440-445; 1971.
6. Vriesendorp, H.M., Epstein, R.B., D'Amaro, J., Westbroek, D.L., and van Rood, J.J. Polymorphism of the DL-A System. *Transplantation* 14:299; 1972.
7. Vriesendorp, H.M. The Occurrence of Dog Histocompatibility Antigen in Other Canidae. *GenenPhaenen* 15:73-78 1972.
8. Westbroek, D.L., Silberbusch, J., Vriesendorp, H.M., van Urk, H., Roemeling, H.W., Schonherr-Scholtes, Y.H.C.H., and de Vries, M.J. The Influence of DL-A Histocompatibility on the Function and Pathohistological Changes in Unmodified Canine Renal Allografts. *Transplantation* 14:582-589; 1972.
9. Vriesendorp, H.M., D'Amaro, J., van der Does, J.A., Westbroek, D.L., and Epstein, R.B. Analysis of the DL-A System in Families and Populations of Healthy and Diseased Individuals. *Transplant. Proc.* 5:311-315; 1973.
10. Vriesendorp, H.M., et al. Joint Report of 1st International Workshop on Canine Immunogenetics. *Tissue Antigens* 3:145-163; 1973.
11. Vriesendorp, H.M. Major Histocompatibility Complex of the Dog. Thesis, Erasmus University, Rotterdam, The Netherlands, 1973.
12. de Gruyl, J., Westbroek, D.L., Dijkhuis, C.M., Vriesendorp, H.M., MacDicken, I., Elion-Gerritsen, W., Verschoor, L., Hulsman, H.A.M., and Horchner, P. Influence of DL-A matching, ALS, and 24-hour Preservation on Isolated Pancreas Allograft Survival. *Transplant. Proc.* 5:755-759; 1973.
13. Grosse-Wilde, H., Vriesendorp, H.M., Wank, R., Mempel, W., Dechamps, B., et al. Definition of Four MLC Specificities in the Dog. *Tissuc Antigens* 4:229-237; 1974.
14. van den Tweel, J.G., Vriesendorp, H.M., Termijden, A., Genetic Aspects of Canine Mixed Leukocyte Cultures. *J. Exp. Med.* 140:825-836; 1974.
15. Vriesendorp, H.M., Duyzer-Den Hartog, B., Smid-Mercx, B.M.J., and Westbroek, D.L. Immunogenetic Markers in Canine Paternity Cases. *J. Small Anim, Pract.* 15:693-699; 1974.

Page 7 **H. M. VRIESENDORP, M.D., Ph.D.**
4/11/2005

16. **Vriesendorp, H.M., Bijnen, A.B., Zurcher, C., and van Bekkum, D.W.**, Donor Selection and Bone Marrow Transplantation in Dogs. p963-971, In: Histocompatibility Testing (F. Kissmeyer-Neilsen, ea.) Copenhagen: Munksgaard, 1975.
17. **Vriesendorp, H.M., Zurcher, C., Bull, R.W., Los, W.R.T., Meera Kahn, P., van den Tweel, J.G., Zweibaum, A., and van Bekkum, D.W.**, GvH and Take of Allogeneic Bone Marrow in Tissue Typed Dogs. *Transplant. Proc.* 7, Suppl. 1, 849-853; 1975.
18. **Vriesendorp, H.M., Zurcher, C., and van Bekkum, D.W.** Engraftment of Allogeneic Dog Bone Marrow. *Transplant. Proc.* 7:465-468; 1975.
19. **Vriesendorp, H.M., Smid-Mercx, B.M.J., Visser, T.P., Halliwell, R.E.W., and Schwarzmann, R.M.** Serological DL-A Typing of Normal and Atopic Dogs. *Transplant. Proc.* 7:375-377; 1975.
20. **Grosse-Wilde, H., Vriesendorp, H.M., Netzel, B., Mempel, W., et al.** Immunogenetics of 7 LD Alleles of the DL-A Complex in Mongrels, Beagles and Labradors. *Transplant. Proc.* 7, Suppl. 1, 159-164; 1975.
21. **Smid-Mercx, B.M.J., Duyzer-den Hartog B., Visser, T.P., and Vriesendorp, H.M.** Serological Studies of Canine Histocompatibility Antigens. *Transplant. Proc.* 7:361-365; 1975.
22. **Leon, S., Zweibaum, A., Vriesendorp, H.M., and Smid, B.M.J.** Production of Tissue Typing Reagents in Rabbits Immunized with Dog Spleen Dry Acetone Powder. *Transplant. Proc.* 7:379-382; 1975.
23. **Westbroek, D.L., Vriesendorp, H.M., de Gruyl, J., van den Tweel, J.G., MacDicken, I., and Jeekel, J.** Influence of SD and LD Matching on Kidney Allograft Survival in Unrelated Mongrel Dogs. *Transplant. Proc.* 7:427-429; 1975.
24. **Bijnen, A.B., Vriesendorp, H.M., de Gruyl, J., van Urk, H., MacDicken, I., Westbroek, D.L.** Blood Transfusion After Grafting of a DL-A Identical Kidney. *Transplant. Proc.* 7:431-433; 1975.
25. **Bull, R.W., Swisher, S.N., Zweibaum, A., and Vriesendorp, H.M.** Inapplicability of CEA7 as a Bone Marrow Transplantation Marker. *Transplant. Proc.* 7:575-577; 1975.
26. **Jeekel, J., Obertop, H., MacDicken, I., Vriesendorp, H.M., and Westbroek, D.L.** Effect of Antidonor Serum and of Donor Cells on Kidney Graft Survival in Tissue Typed Littermate Beagles. *Transplant. Proc.* 7:435-438; 1975.
27. **Obertop, H., Jeekel, J., Vriesendorp, H.M., MacDicken, I., and Westbroek, D.L.** The Effect of Donor Blood on Renal Allograft Survival in DL-A Tissue Typed Beagle Littermates. *Transplantation* 20:49-52; 1975.
28. **Leon, S., Vriesendorp, H.M., Zweibaum, A., Flech-Sebau, C., and Chevalier, G.** Application a L'etude Serologique du Systeme Majeur d'Histocompatibilite du Chien (DLA) des Proprietes Antigeniques et Immunogenes de la Poudre Actonique de Rate. *C.R. Acad. Sc. Paris Serie D281*: 1653-1656; 1975.
29. **Vriesendorp, H.M., Albert, E.D., Templeton, J.W., Belotsky, S., Taylor, B., Bull, R.W., Epstein, R.B., Ferrebee, J.W., Grosse-Wilde, H., Hammer, C., Krumbacher, K., Leon, S., Meera Khan, P., Mickey, M.R., Motola, M., Saison, R., Schnappauf, H., Scholz, S., Schroeder, M.L., Storb, R., Wank, R., Westbroek, D.L., and Zweibaum, A.** Joint Report of the 2nd International Workshop on Canine Immunogenetics. *Transplant. Proc.* 8:289-311; 1976.

Page 8 H. M. VRIESENDORP, M.D., Ph.D.
4/11/2005

30. **Vriesendorp, H.M., Lowenberg, B., Visser, T.P., Knaan, S., and van Bekkum, D.W.** The Influence of Genetic Resistance and Silica Particles on Survival After Bone Marrow Transplantation. *Transplant. Proc.* 8:483-489; 1976.
31. **Bijnen, A.B., Vriesendorp, H.M., Grosse Wilde, H., and Westbroek, D.L.** Polygenic Control of Mixed Lymphocyte Cultures in Dogs. *Tissue Antigens* 9:187-194; 1977.
32. **Visser, J., Vriesendorp, H.M., and Visser, T.P.** Cryopreservation of Dog Bone Marrow. p 113-118, In: *Cryoimmunology* (D. Simatos, D.M. Strong, and J.M. Turc, eds.) Paris: INSERM; 1977.
33. **Singh, R., Vriesendorp, H.M., Michielse, K., and Stefanko, S.** Nerve Allografts and Histocompatibility in Dogs. *J. Neurosurg.* 47:737-743, 1977.
34. **Vriesendorp, H.M., Bijnen, A.B., Westbroek D.L., and van Bekkum, D.W.** Genetics and Transplantation Immunology of the DLA Complex. *Transplant. Proc.* 9:293-296; 1977.
35. **Obertop, H., Bijnen, A.B., Vriesendorp, H.M., and Westbroek, D.L.** Effects of Subcutaneous Injections of Kidney Donor Blood on Renal Allograft Survival in DLA Typed Dogs. *Transplantation* 26:201-202; 1978
36. **Bull, R.W., Vriesendorp, H.M., Obertop, H., Bijnen, A.B., Jeckel, J., de Gruyl, J., and Westbroek, D.L.** The Effect of Prior Third Party Blood Transfusions on Canine Renal Allograft Survival. *Transplantation* 26:249-354; 1978.
37. **Obertop, H., Bijnen, A.B., Vriesendorp, H.M., and Westbroek, D.L.** Prolongation of Renal Allograft Survival in DLA Tissue Typed Beagles after Third Party Blood Transfusion and Immunosuppressive Treatment. *Transplantation* 26:255-259; 1978.
38. **Obertop, H., Bijnen, A.B., Vriesendorp, H.M., and Westbroek, D.L.** The Effect of Prior Parental Blood Transfusions on the Survival of Renal Allografts from a DLA Identical Sibling. *Transplantation* 26:388-390; 1978.
39. **Meera Khan P, Vriesendorp H, Saison R, Volkens WS, Los WR, Doppert BA.** Linkage between PGM₃ and the genes determining the major histocompatibility complex (MHC) in *canis familiaris* (the domestic dog). *Cytogenet Cell Genet* 22: 585-7; 1978
40. **van Bekkum, D.W., Wagemaker, G., and Vriesendorp, H.M.** Mechanisms and Avoidance of Graft Versus Host Disease. *Transplant. Proc.* 11:189-194; 1979.
41. **Visser, J.W.M., van den Engh, G., Vriesendorp, H.M.** Bloed Cellen: Aanmaak en Verbruik In Dynamisch Evenwicht. *Para Medica* 2: 17-22; 1979.
42. **Bijnen, A.B., Byma-Dekkers, A.M., Vriesendorp, H.M., and Westbroek, D.L.** Value of the Mixed Lymphocyte Reaction in Dogs as a Genetic Assay. *Immunogenetics* 8:287-297; 1979.
43. **Bijnen, A.B., Byma-Dekkers, A.M., Vriesendorp, H.M.** Genetics of Kidney Allograft Survival in Dogs I. Relevance of Subregions of the Major Histocompatibility Complex in recipients without immunosuppression. *Transplantation* 28:186-190; 1979.
44. **Bijnen, A.B., Westbroek, D.L., Obertop, H., van Urk, H., Vriesendorp, H. M.** Genetics of Kidney Allograft Survival in Recipients without Immunosuppressive Therapy. *Transplantation* 28: 191 - 195; 1979.
45. **Lansdorp, P.M., Vriesendorp, H.M., Betton, G.R., and Bijnen, A.B.** Secondary Responses of Alloantigen Primed Dog Lymphocytes. *Tissue Antigens* 15:40-46; 1980.

Page 9 H. M. VRIESENDORP, M.D., Ph.D.
4/11/2005

46. Vriesendorp, H.M., and Klapwijk, W.M. Toepassing van Antibiotica in Bestraalde Honden. *Biotechniek* 19:84-89; 1980.
47. Sintnicolaas, K., Vriesendorp, H.M., Sizoo, W., Stenfert Kroese, W.F., Haye, W.G., Hop, W.C.J., Abels, J., and Lowenberg, B. Delayed Alloimmunization by Random Single Donor Platelet Transfusions. *Lancet* i, 750-754; 1981.
48. Vriesendorp, H.M., Wagemaker, G., and van Bekkum, D.W. Engraftment of Allogeneic Bone Marrow. *Transplant. Proc.* 13:643-648; 1981.
49. Wagemaker, G., Vriesendorp, H.M., and van Bekkum, D.W. Successful Bone Marrow Transplantation Across Major Histocompatibility Barriers in Rhesus Monkeys. *Transplant. Proc.* 13:875-880; 1981.
50. Lowenberg, B., Sizoo, W., Sintnicolaas, K., Scholzel, C., Hendriks, W.D.H., Vriesendorp, H.M., Wagemaker, G., and van Bekkum, D.W. Successful autologous bone marrow transplantation in a patient with acute myeloid leukemia. p54. In: *Proceedings Symposium on Bone Marrow Transplantation*. Courchevel, Excerpta Medica, Amsterdam; 1981.
51. Vriesendorp, H.M., Klapwijk, W.M., van Kessel, A.C.M., Zurcher, C., and van Bekkum, D.W. Lasting Engraftment of Histoincompatible Dog Bone Marrow Cells. *Transplantation* 31:347-352; 1981.
52. Vriesendorp, H.M., Heidt, P.J., Zurcher, C. Gastrointestinal Decontamination of Dogs Treated with Total Body Irradiation and Bone Marrow Transplantation. *Exp. Hematol.* 9:904-916; 1981.
53. Vriesendorp, H.M., and Zurcher, C. Late Effects of Total Body Irradiation in Dogs Treated with Bone Marrow Transplantation. p71-79 in: *Proceedings Meeting of European Late Effects Project Group of EURATOM. on Late Effects of Whole Body Irradiation*: 1981.
54. Singh, R., Vriesendorp, H.M., Michielse, G., and Stefanko, S. Cadaver Nerve Allografts in Dogs. *Biomedicine* 35:67-73; 1981.
55. Heidt, P.J., Vriesendorp, H.M., Zurcher, C., de Groot, C.W., and Klapwijk, W.M. Selective Gastrointestinal Decontamination in Dogs Undergoing Allogenic Bone Marrow Transplantation. p579-582, In: S. Sasahi et al. (eds) *Recent Advances in Germ Free Research*. Tokai University Press; 1981.
56. Vriesendorp, H.M., Klapwijk, W.M., Visser, T.P., Zurcher, C., and van Bekkum, D.W. Alternatives to Donor Matching for Control of Graft-Versus-Host Disease. *Immunogenetics* 15:79-94; 1982.
57. Vriesendorp, H.M., Klapwijk, W.M., Heidt, P.J., Hogeweg, B., Zurcher, C., and van Bekkum, D.W. Factors Controlling the Engraftment of Transplanted Dog Bone Marrow Cells. *Tissue Antigens* 20:63-80; 1982.
58. Castagnola, C., Walma, E.P., Vriesendorp, H.M., and van Bekkum, D.W. Trapianto di Midollo Osseo Dopo Arricchimento di Cellule Steminali con Gradiente di Albumina Nel Cane, p419-425, In: *Il Trapianto Oggi, Centro Transfusionale Ospedale Policlinico di Milano* Editore Milan; 1982.
59. Vriesendorp H.M. Bone marrow graft survival after total body irradiation in dogs. *Transplantation* 1982; 34: 312
60. Vriesendorp, H.M., Kies, M.S., and Kucuk, O: Bone Marrow Transplantation, From Greek Monster to a Day in the Sun. *Cancer Focus* 5: 17-23; 1982.

**Page 10 H. M. VRIESENDORP, M.D., Ph.D.
4/11/2005**

61. Rosen, S.T., Maciorowski, Z., Witlin, F., Epstein, A.L., Gordon, L.I., Kies, M.S., Kucuk, O., Kwaan, H.C., Vriesendorp, H.M., Winter, J.N., Fors, E., and Molteni, A.: Estrogen Receptor Analysis in Chronic Lymphocytic Leukemia. *Blood* 62:996-699; 1983.
62. Vriesendorp, H.M. Radiation and the Hemopoietic System. p335-339, In: *Proceedings of the 7th International Congress of Radiation Research* (Broerse, Barendsen, Kal, van der Kogel, eds.) Amsterdam: Martinus Nijhoff; 1983.
63. Kucuk, O., Gordon, L.E., Kies, M.S., Spies, S., Spies, W., and Vriesendorp, H.M. Estimation of Hemopoietic Potential by CFU and Bone Marrow Scan in Cancer Patients. *Exp. Hematol.* 12:101-106; 1984.
64. Gordon, L.I., Rosen, S.T., Vriesendorp, H.M., Kies, M.S., and Kucuk, O.: Separation of Clonogenic Tumor Cells from Small Cell Lung Cancer Cell Lines. *Cancer Res.* 44:5404-5408; 1984.
65. Soper, W.D., Pasini, J., Fey, T., and Vriesendorp, H.M.: The Influence of Passenger Leukocytes on the Survival Time of DLA Identical Kidney Allografts from Radiation Chimeras. *Transplant. Proc.* 17:863-865; 1985.
66. Vriesendorp, H.M., Johnson, P.M., Fey, T.A., McDonough, C.M., Zoetelief, J., and van Bekkum, D.W. Optimal Dose of Total Body Irradiation for Allogeneic Bone Marrow Transplantation. *Transplant. Proc.* 17:517-520; 1985.
67. Vriesendorp, H.M., Halliwell, R.E., Johnson, P.M., Fey, T.A., and McDonough, C.M. Immunoglobulin Levels in Dogs After Total Body Irradiation and Bone Marrow Transplantation. *Transplantation* 39:583-588; 1985.
68. Vriesendorp, H.M. Optimal Prescription Method for Cancer Chemotherapy. *Exp. Hematol.* 13:Suppl. 16, 57-63; 1985.
69. Doxiadis, G., Rebmann, V., Doxiadis, L., Krumbacher, K., Vriesendorp, H.M., and Grosse-Wilde, H. Polymorphism of the Fourth Complement in the Dog. *Immunobiology* 169:563-569; 1985.
70. Walma, E.P., Vriesendorp, H.M., Zurcher, C., and van Bekkum, D.W. Engraftment of Stem Cell Enriched Bone Marrow Fractions in MHC Identical Dogs after Fractionated Total Body Irradiation. *Transplantation* 43: 81-89; 1987.
71. Bull, R.W., Vriesendorp, H.M., Cech, R., Grosse-Wilde, H., Bijnen, A.M., Ladiges, W.L., Krumbacher, K., Doxiadis, I., Ejina, H., Templeton, J., Albert, E.D., Storb, R., and Deeg, H.J. Joint Report of the Third International Workshop on Canine Immunogenetics II Analysis of the Serological Typing of Cells. *Transplantation* 43: 154-161; 1987.
72. Vriesendorp, H.M., Vriesendorp, R., and Vriesendorp, F.J. Prediction of Normal Tissue Damage Induced by Cancer Chemotherapy. *Cancer Chemotherapy and Pharmacology*, 19:273-276; 1987.
73. Vriesendorp, H.M., Johnson, P.M., Monroy, R.L., MacVittie, T.J., and van Bekkum, D.W. Influence of Three Interrelated Total Body Irradiation Parameters -Quality, Dose, Nonuniformity on Outcome of Allogeneic Bone Marrow Transplantation in Dogs. pp 141-148 in: Progress in Bone Marrow Transplantation. p 141, Galè, R.P. and Champlin, R., (eds.) Alan R. Liss, Inc., New York, 1987.
74. Monroy, R.L., Vriesendorp, H.M., and MacVittie, T.J. Improved Survival of Dog Exposed to Fission Neutron Radiation and Transplanted with DLA Identical Bone Marrow. *Bone Marrow Transplantation*, 2:375-384; 1987.

Page 11 **H. M. VRIESENDORP, M.D., Ph.D.**
4/11/2005

75. **Vriesendorp H.M.** Rejection of allogeneic bone marrow cells. *Blood* 1987; 701: 889-90.
76. **Kies, M.K., Gordon, L.I., Rosen, S.T., Kucuk, O., and Vriesendorp, H.M.** Autologous Bone Marrow Transplantation in Breast Cancer: Separation of Clonogenic Tumor Cell Colonies by Gradient Fractionation. *Exp. Hematol.* 16: 190-194; 1988.
76. **Wingard, J.R., Mellits, E.D., Sostrin, M.B., Chen, D., Y-H., Burns, W.H., Santos, G.W., Vriesendorp, H.M., Beschoner, W.E., and Saral, Rein.** Interstitial Pneumonitis After Allogeneic Bone Marrow Transplantation. Nine-Year Experience at a Single Institution. *Medicine* 67:175-187; 1988.
77. **Vriesendorp, H.M., MacVittie, T.J.** Animal Models for Radiation Accidents. *Bone Marrow Transplantation: Current Controversies. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 91.* Editors, R.P. Gale & R. Champlin. p.659-670, Alan R. Liss, Inc., New York, NY (1988).
78. **Order, S.E., Vriesendorp, H.M., Klein, J.L., and Leichner, P.K.** A Phase I Study of ⁹⁰Yttrium Antiferritin: Dose Escalation and Tumor Dose. *Antibody Immunoconjugates, and Radiopharmaceuticals* 1:163-168; 1988.
79. **Wingard, J.R., Sostrin, M.B., Vriesendorp, H.M., Mellits, E.D., Santos, G.W., Fuller, D.J., Braine, H.G., Yeager, A.M., Burns, W.J., and Saral, R.** Interstitial Pneumonitis Following Autologous Bone Marrow Transplantation. *Transplantation* 46:61-65; 1988.
80. **Vriesendorp, H.M., and Williams, J.R.** Radiation Sensitivity of Transplanted Bone Marrow Cells. *Transplantation* 46:784; 1988.
81. **Vriesendorp, H.M., Herpst, J.M., Leichner, P.K., Klein, J.L., and Order, S.E.** Polyclonal ⁹⁰Yttrium Labeled Antiferritin for Refractory Hodgkin's Disease. *Int. J. Radiat. Biol. Phys.* 17:815-821; 1989.
82. **Vriesendorp, H.M., and Order, S.E.** Hodgkin's Disease: New Possibilities for Clinical Research (Editorial), *Int. J. Radiat. Biol. Phys.* 17:1119-1121; 1989.
83. **Vignuelle, R.M., Vriesendorp, H.M., Taylor, P., Burns, W., and Pekley, T.** Survival after Total-Body Irradiation. I Effects of Partial Intestinal Shielding. *Radiation Research.* 119:313-324; 1989.
84. **Holland, H.K., Saral, R., Rossi, J.J., Donnenberg, A.D., Burns, W.H., Beschoner, W.M., Faradegan, H., Jones, R.J., Quinnan, G.V., Vogelsang, G.V., Vriesendorp, H.M., Wingard, J.R., Zaia, J.A., and Santos, G.W.:** Allogeneic Bone Marrow Transplantation, Zidovudine, and Human Immunodeficiency Virus Type I (HIV-1) Infection: Studies in a Patient with Non-Hodgkin Lymphoma, *Ann. Intern. Med.* 111, 973-979; 1989.
85. **Vriesendorp, H.M.** Radiobiological Speculations on Therapeutic Total Body Irradiation. *Critical Reviews in Oncology/Hematology* 10:211-224; 1990.
86. **Vriesendorp, H.M.** Prediction of Effects of Therapeutic Total Body Irradiation. *Radiation and Oncology.* 20, Suppl 1, 37-50; 1990.
87. **R.J.Jones, S. Piantadosi, R.B. Mann, R.F. Ambinder, E.J. Seifter, H.M. Vriesendorp, M.D. Abeloff, W.H. Burns, S.D. Rowley, G.B. Vogelsang, J.E. Wagner, J.M. Wiley, J.R. Wingard, A.M. Yeager, R. Saral and G.W. Santos:** High-Dose Cytotoxic Therapy and Bone Marrow Transplantation for Relapsed Hodgkin's Disease. *J. Clin. Oncol.* 8:527-537; 1990.

Page 12 **H. M. VRIESENDORP, M.D., PhD.**
4/11/2005

88. Wingard, J.R., Piantadosi, S., Santos, G.W., Saral, R., Vriesendorp, H.M., Yeager, A.M., Burns, W.H., Ambinder, R.F., Braine, H.G., Elfenbein, G., Jones, R.J., Haizer, H., May, W.S., Rowley, S.D., Sensenbrenner, L.L., Stuart, R.K., Tutschka, P.J., Vogelsang, G.B., Wagner, J.E., Beschoner, W.E., Brookmeyer, R., and Farmer, E.R.: Allogeneic Bone Marrow Transplantation for Patients with High-Risk Acute Lymphoblastic Leukemia. *J. Clin. Oncol.* 8:820-830; 1990.
89. Siegel, J.A., Wessels, B.W., Watson, E.E., Stabin, M.G., Vriesendorp, H.M., Bradley, E.W., Badger, C.C., Brill, A.B., Kwok, C.S., Stickney, D.R., Eckerman, K.F., Fisher, D.R., Buschbaum, D.J., and Order, S.E.: Bone Marrow Dosimetry and Toxicity for Radioimmunotherapy. *Antibody, Immunoconjugates, and Radiopharmaceuticals* 3:213-233; 1990.
90. Vriesendorp, H.M.: Radiation Injury to Hemopoietic Cells: Target Cells, Species Differences, and Dose Distribution. *Antibody, Immunoconjugates, and Radiopharmaceuticals* 3:293-302; 1990.
91. Vriesendorp, H.M., Herpst, J.M., Germack, M.A., Klein, J.L., Leichner, P.K., Loudenslager, D.M., and Order, S.E.: Phase I-II studies of Yttrium labeled antiferritin treatment for Relapsed Hodgkin's Disease, including RTOG 8701. *J. Clin. Oncol.* 9:918-928; 1991.
92. Vriesendorp, H.M., Quadri, S.M., Stinson, R.L., Onyekwere, O.C., Shao, Y., Klein, J.L., Leichner, P.K., and Williams, J.R.: Selection of reagents for human radioimmunotherapy. *Int. J. Radiat. Biol. Phys.* 22:37-46; 1991.
93. Quadri, S.M., Vriesendorp, H.M., Leichner, P.K. and Williams, J.R. Linker modulated biodistribution of In-111 and Y-90 labeled monoclonal antibody antiferritin immunoconjugates in nude mice and dogs. *In* Dicke, K.A. and Armitage, J.O. (eds.) *Proceedings of the 5th International Symposium on Autologous Bone Marrow Transplantation*, Omaha, NE, 711-722; 1991.
94. Vriesendorp, H.M., Quadri, S.M., Leichner, P.K., Klein, J.L., Dicke, K.A., Bierman, P.J. and Williams, J.R.: Incorporation of radiolabeled immunoglobulin administration in conditioning regimens for bone marrow transplantation. *In* Dicke, K.A. and Armitage, J.O. (eds.) *Proceedings of the 5th International Symposium on Autologous Bone Marrow Transplantation*, Omaha, NE, 723-732; 1991.
95. Leichner, P.K., Vriesendorp, H.M., Hawkins, W.G., Quadri, S.M., Yang, N.C., Stinson, R.L., Loudenslager, D.M., Frenkel, T.L., Chen, X.Y. and Klein, J.L. Quantitative SPECT for Indium-111 labeled antibodies in the liver of beagle dogs. *J. Nucl. Med.* 32:1442-1444; 1991.
96. Vriesendorp, H.M., Herman, M.G., and Saral, R. Future Analyses of Total Body Irradiation. *Int. J. Radiat. Oncol. Biol. Phys.* 20:635-637; 1991
97. Vriesendorp, H.M. Influence of Radiation Dose and Radiation Field Size on the Induction or Treatment of Leukemia. *Seminars in Hematology.* 28(4):25-31; 1991.
98. Vriesendorp, H.M. Erratum for "Presidential address: systemic radiotherapy-the new frontier" by S Order. *Int J Radiat Oncol Biol Phys* 1991;21: 1676
99. Wingard, J.R., Plotnick, L.P., Freemer, C.S., Zahurak, M., Piantadosi, S., Miller, D.F., Vriesendorp, H.M., Yeager, A.M. and Santos G.W. Growth in Children After Bone Marrow Transplantation: Busulfan Plus Cyclophosphamide Versus Cyclophosphamide Plus Total Body Irradiation. *Blood.* 79:1068-1073; 1992.

Page 13 H. M. VRIESENDORP, M.D., PhD.
4/11/2005

100. **Vriesendorp, H.M.**, Vigneulle, R.M., Kitto, G., Pelky, T., Taylor, P., and Smith, J.: Survival after total body irradiation. Effects of irradiation of Exteriorized Small Intestine. *Radiation and Oncology* 23: 160-169; 1992.
101. **Quadri, S.M.**, Shao, I., Blum, J.E., Leichner, P.K., Williams, J.R. and **Vriesendorp, H.M.** Comparison of intravenously administered ¹¹¹In and ⁹⁰Y labeled site specific B72.3 immunoconjugate (GYK-DTPA) in beagle dogs. *Nucl. Med. Biol.* 20:559-570; 1993.
102. **Vriesendorp, H.M.**, Shao, I., Blum, J.E., Quadri, S.M. and Williams, J.R. Fractionated intravenous administration of site specific Yttrium-90 labeled B72.3 GYK DTPA immunoconjugate in beagle dogs. *Nucl. Med. Biol.* 20:571-580; 1993.
103. Gordon, L.I., Shapiro, G.I., Rosen, S.T., Kies, M.S., Prachand, S. and **Vriesendorp, H.M.** Separation of chronic lymphocytic leukemia (CLL) cells by a discontinuous density gradient: correlation with clinical stage (1993), *International Journal of Oncology*, in press.
104. Bierman, P.J., Vose J.M., Leichner, P.K., Quadri S.M., Armitage, J.O., Klein, J.L., Abrams, R.A., Dicke, K.A., and **Vriesendorp, H.M.** ⁹⁰Yttrium-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor prognosis Hodgkin's disease. *J. Clin. Oncol.* 11:698-703; 1993.
105. **Quadri, S.M.**, **Vriesendorp, H.M.**, Leichner, P.K. and Williams J.R. Evaluation of ¹¹¹Indium- and ⁹⁰Yttrium- labeled linker immunoconjugates in nude mice and dogs. *J. Nucl. Med.* 34:935-945; 1993.
106. **Quadri, S.M.**, Lai J., Mohammedpour H., **Vriesendorp, H.M.**, and William J.R. Assessment of radiolabeled stabilized F(ab')₂ fragments of monoclonal antiferritin in nude mouse model. *J. Nucl. Med.* 34:2251-2258; 1993.
107. **Vriesendorp, H.M.**, Dicke, K.A., Quadri, S.M. Radioimmunotherapy for bone marrow transplantation patients. In *Proceedings Sixth Autologous Bone Marrow Transplantation Conference* Dicke KA and Keating A (eds) pp 98-102, 1993. Cancer Treatment Research Education Fund, Arlington, Texas.
108. **Khoury, I.F.**, Keating, M.J. **Vriesendorp, H.M.** Reading, C.C. Przepiorka, D., Hub, Y.O., Anderson, B.S., van Besien, K.W., Mehra, R.C., Giralt, S.A., Ippoliti, C., Marshall, M., Thomas, M.W. O'Brien, S., Robertson, L.E., Deisseroth, A. and Champlin, R.E. Autologous and Allogeneic bone marrow transplantation for chronic lymphocytic leukemia. *J. Clin Onc.* 12:748-758; 1994.
109. **Przepiorka, D.**, Ippoliti, C., Koberda, J., Chan, K.W., Khoury, I., Fischer, H.E., Hub, Y.O., Escudier, S., Seonge, P., Davis, M., Gajewski, J. **Vriesendorp, H.M.**, Champlin R.E. Interleukin-2 for prevention of graft versus host disease after haploidentical marrow transplantation. *Transplantation* 58:858-860; 1994.
110. **Vriesendorp, H.M.**, Chu, H., Ocharan, T., Besa, P., Champlin, R.E. Radiobiology of total body irradiation. *Bone Marrow Transplantation* 14, Suppl. 4, S4-S8; 1994.
111. **Giralt, S.A.**, LeMaistre, C.F., **Vriesendorp, H.M.**, Andersson, B.S., Dimopoulos, M., Gajewski, J., Van Besien, K., Mehra, R., Przepiorka, D., Khoury, I., Yan, J., Kantarjian, H., Deisseroth, A.B., Champlin, R.E. Etoposide, cyclophosphamide, total body irradiation and allogeneic bone marrow transplantation for hematologic malignancies. *J. Clin. Oncol* 1994; 12: 1923-30.

Page 14 **H. M. VRIESENDORP, M.D., PhD.**
4/11/2005

112. Herpst, J.M., Klein, J.L., Leichner, P.K., Quadri, S.M., **Vriesendorp, H.M.** Survival of patients with resistant Hodgkin's Disease after polyclonal ⁹⁰Yttrium-labeled antiferritin treatment. *J. Clin. Oncol.* 13:2394-2400; 1995.
113. Wang, S., Quadri, S.M., Tang, X.Z., Stephens, L.C., Lollo, C.P., Bartholomew, R.M., **Vriesendorp, H.M.** Liver toxicity induced by combined external beam irradiation and radioimmunoglobulin therapy. *Rad. Research* 141:294-302; 1995.
114. Quadri, S.M., Siddiqui, A., Klein, J.L. and **Vriesendorp, H.M.** Biodistribution and tumor localization of ¹¹¹Indium-labeled unmodified and modified F(ab')₂ fragments of human monoclonal IgM (16.88) in a nude mouse model. *Nucl. Med. Biol.* 22:425-435; 1995.
115. **Vriesendorp, H.M.**, Chu, H., Ochran, T., Besa, P., Champlin, R.E. Total body irradiation and the therapeutic ratio of bone marrow transplantation. *Bone Marrow Transplantation* 15, Suppl. 1:5193-5198; 1995.
116. Siddiqui, A., Quadri, S.M., Griffiths, G.L., Goldenberg, D.M., **Vriesendorp, H.M.** Tumor targeting and pharmacokinetics of unmodified and modified F(ab')₂ fragments of an anti-CEA murine monoclonal antibody (Immu-14). *Nucl. Med. Biol.* 22:425-435; 1995.
117. Quadri, S.M., **Vriesendorp, H.M.** Improved radioimmunoconjugates for cancer treatment. In *Proceedings 7th International Autologous Bone Marrow Transplantation Conference*, Dicke, KA and Keating, A (eds). The Cancer Treatment Research Education Fund, Arlington, Texas, pp 697-708; 1995.
118. **Vriesendorp, H.M.**, Quadri, S.M. Hodgkin's Disease, a perpetual paradigm for new therapeutic approaches. In *Proceedings 7th International Autologous Bone Marrow Transplantation Conference*, Dicke, KA and Keating, A (ed). The Cancer Treatment Research and Educational Institute, Arlington, Texas, pp 709-720; 1995.
119. **Vriesendorp, H.M.**, Quadri, S.M. Prospects for more rapid and safer development of clinical radiolabeled immunoglobulin therapy. In *Proceedings 7th International Autologous Bone Marrow Transplantation Conference*, Dicke, KA and Keating, A (ed). The Cancer Treatment Research and Educational Institute, Arlington, Texas, pp 735-745; 1995.
120. Quadri, S.M., Malik, A., Tang, X-Z, Patenia, R., Freedman, R.S., **Vriesendorp, H.M.** Preclinical analysis of intraperitoneal administration of ¹¹¹Indium-labeled human tumor reactive monoclonal IgM AC6C3-2B 12. *Cancer Research* 55:5736s-5742s; 1995.
121. **Vriesendorp, H.M.**, Morton, J.D., Quadri, S.M. A review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's Disease. *Cancer Research* 55:5888s-5892s; 1995.
122. Przepiorka, D., Chan, K-W, Champlin, R.E., Culbert, S.J., Petropoulos, D., Ippoliti, C., Khouri, I., Huh, Y.O., **Vriesendorp, H.M.**, Deisseroth, A.B., Bleyer, W.A. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. *Bone Marrow Transplantation* 16:737-741; 1995.
123. **Vriesendorp, H.M.**, Quadri, S.M., Andersson, B.S., Dicke, K.A. Hematological side effects of radiolabeled immunoglobulin therapy. *Experimental Hematology*, 24:1183-1190; 1996

Page 15 **H. M. VRIESENDORP, M.D., PhD.**
4/11/2005

124. **Vriesendorp, H.M.**, Quadri, S.M., Jaecle, K.A., Freedman, R.S., Cromeens, D.M.
A proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy. *Radiotherapy & Oncology*, 1996; 41: 151-161
125. Quadri SM, Malik AB, Chu HB, Freedman RS, **Vriesendorp HM** Intraperitoneal indium-11 and yttrium-90 labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis. *J Nucl Med* 1996; 37: 1545-51
126. **Vriesendorp H.M.** Systemic radiotherapy with monoclonal antibodies: Options and problems, book review. *J.Natl.Cancer Inst.* 88 : 1405, 1996
127. **Vriesendorp, H.M.**, Wyllie, C.T., Quadri, S.M., Anderson, B.S., Dicke, K.A., Therapeutic ratio of yttrium-90 labeled antiferritin (AF) therapy for recurrent Hodgkin's Disease.p.625-638 In proceedings 8th International Blood and Marrow Transplantation Conference. Dicke, K.A. and Keating, A. (eds). Carden Jennings, Charlottesville, Virginia, 1997
128. **Vriesendorp, H.M.**, Quadri, S.M., Andersson, B.S., Wyllie, C.T., Dicke, K.A. Recurrence of Hodgkin's Disease after yttrium-90 labeled antiferritin treatment, *Cancer,suppl.* December 1997, 2771-2727.
129. **Vriesendorp, F.J.**, Quadri, S.M., Flynn, R.E., Malone, M.R., Cromeens, D.M., Stephens, L.C., **Vriesendorp, H.M.** Preclinical analysis of radiolabeled anti GD2 IgG. *Cancer,suppl.* December 1997, 2642- 2649.
130. Quadri, S.M., Borchardt, P.E., Weinstein G.D., Freedman, R.S., **Vriesendorp, H.M.** Intralesional administration of radiolabeled immunoglobulin for human solid tumors.p.663-672 In proceedings 8th International Blood and Marrow Transplantation Conference. Dicke, K.A. and Keating, A. (eds). Carden Jennings, Charlottesville, Virginia, 1997
131. Borchardt, P.E., Quadri, S.M., Freedman, R.S., **Vriesendorp, H.M.** Intralesional radiolabeled human monoclonal IgM in human tumor xenografts. *Radiotherapy & Oncology*,44, 283-93, 1997
132. Khouri IF, Przepiora D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RJ, **Vriesendorp HM**, Andersson BS, Giralt S, Korbling M, Keating MJ, Champlin RE. Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: timing of transplantation and potential effect of fludarabine on acute graft versus host disease *Br J Haematol* 1997; 97: 466-73
133. Borchardt, P.E., Quadri, S.M., Freedman, R.S., **Vriesendorp, H.M.** Intraperitoneal radiolabeled human monoclonal IgM in nude mice bearing peritoneal nodules of human ovarian cancer. *J.Nucl.Med.* 1998; 39: 476-84
134. **Vriesendorp H.M.**, Quadri S.M., Borchardt P.E., Tumor Therapy with Radiolabeled Antibodies: Optimization of Therapy. *Biodrug*, 1998; 4: 275-293.
135. **Vriesendorp H.M.**, Quadri S.M., Borchardt P.E., **Vriesendorp F.J.** Studies of Volume effects of Radiation in Large Animals. In Proceedings Fifth International Conference on Dose, Time and Fractionation in Radiation Oncology. Volume & Kinetics in Tumor Control & Normal Tissue Complications. Paliwal BR, Fowler JF, Herbert DE, Mehta MP eds. pp 218-229. Medical Physics Publishing, Madison Wisconsin, 1998 for American Association of Physicists in Medicine.
136. Quadri, S.M., **Vriesendorp H.M.**, Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. *The Quarterly Journal of Nuclear Medicine* 42: 250-261; 1998.

Page 16 **H. M. VRIESENDORP, M.D., Ph.D.**
4/11/2005

137. **Vriesendorp HM.** The next (third) dimension to dosing of anticancer agents. *J Clin Oncol* 1998; 16: 3715-16(Letter to Editor)
138. **Vriesendorp HM, Quadri S.M, Wyllie C.T, Lai J, Borchardt P.E, Harris L, Wucher R, Askew E, Schweichler L.** Fractionated Radiolabeled Antiferriin Therapy for Patients with Recurrent Hodgkin's disease. *Clin Canc Res* 1999; 5: 3324s-3329s
139. **Lai J, Quadri S.M, Borchardt P.E, Harris L, Wucher R, Askew E, Schweichler L, Vriesendorp HM.** Pharmacokinetics of Radiolabeled Polyclonal Antiferriin in Patients with Hodgkin's disease. *Clin Canc Res* 1999; 5: 3315s-3323s
140. **Vriesendorp HM, Quadri S.M.** Radiolabeled Immunoglobulin Therapy in Hodgkin's disease. An Update. *Cancer Biotherapy Radiopharm Cancer* 2000; 15: 431-445
141. **van Bekkum D.W, Vriesendorp HM.** Translational research for allogeneic bone marrow transplantation. *N.Eng.J.Med*,1999; 340: 809-810 (Letter to Editor)
142. **Borchardt P.E., Quadri S.M., Freedman R.S., Vriesendorp HM.** Intraperitoneal radioimmunotherapy with human monoclonal IgM in nude mice with peritoneal carcinomatosis. *Cancer Biotherapy Radiopharm* , 2000; 15: 53-64.
143. **Vriesendorp HM, Vriesendorp FJ.** Intravenous administration of radiolabeled IgG. High or low protein dose? *Cancer Biotherapy Radiopharm* 2003; 18:35-46
144. **Vriesendorp HM.** Mind over Method. Letter to the Editor. *Int J Radiat Oncol Biol Phys* 2001; 51: 280-281
145. **Vriesendorp HM, Quadri SM.** Barriers and Opportunities for Radiolabeled Immunoglobulin Therapy, *Expert Rev Anticancer Ther*, 2001, 1: 461-478
146. **Vriesendorp HM.** Aims of Conditioning, *Exp Hematol* 2003; 31: 844-854
147. **Vriesendorp HM, van Bekkum DW.** Conditioning for Hemopoietic Stem Cell Transplantation with Total Body Irradiation, Total Lymphoid Irradiation and Immunoglobulins, 2004 submitted
148. **Vriesendorp HM, van Bekkum DW.** Conditioning for Hemopoietic Stem Cell Transplantation with Radiolabeled Immunoglobulins Agents, 2004 submitted
149. **Borchardt P.E., Vriesendorp HM, Freedman R.S., Quadri SM.** Intralesional Radioimmunotherapy with Yttrium-90 labeled human monoclonal IgM in nude bearing human tumor xenografts. *Cancer Biotherapy Radiopharm* 2004;19: 43-54

Page 17 H. M. VRIESENDORP, M.D., Ph.D.
4/11/2005

Book Sections

1. **Vriesendorp, H.M.** Similarities Between HL-A and Major Histocompatibility Complexes of Subhuman Primates. p 539, In: *Progressi nei Trapiante D'organo e Negli Organi Artificiali*. C. Scotti Foglieni, G. Pedroni, G.S. Donati, R. Cortesini, R. Cortinovis (Eds.) La Tipografica Varese, 1976.
2. **Vriesendorp, H.M.**, Grosee Wilde, H. W., and Dorf, M. E. The Major Histocompatibility Complex of the Dog. p 129, In: The Major Histocompatibility System in Man and Animals (d. Gotze, ed.) Berlin: Springer, 1977.
3. **Vriesendorp, H.M.**, Bijnen, A.B., van Kessel, A.C.M., Obertop, H., and Westbroek, D.L. Minor Histocompatibility Systems in Dogs. p 109, In: *Experimental Hematology Today*. New York: Springer, 1978.
4. van Bekkum, D.W., Lowenberg, B., and **Vriesendorp, H.M.** Bone Marrow Transplantation. In: Immunological Engineering (D.A. Yirsh, ed.) Lancaster, England: MTP Press, LTD., 1978.
5. **Vriesendorp, H.M.** Applications of Transplantation Immunology in Dogs. In: *Advances in Veterinary Science and Comparative Medicine* (Bradley and Cornelius, eds.) Vol. 23, 299, 1979.
6. **Vriesendorp, H.M.**, and van Bekkum, D.W. Role of Total Body Irradiation in Conditioning for Bone Marrow Transplantation. In: Immunobiology of Bone Marrow Transplantation (S.Thierfelder, H. Rodt, H. Kolb, eds.) Heidelberg: Springer Verlag, 1980. p.349-364
7. **Vriesendorp, H.M.** Dog Histocompatibility Testing. p134, In: The Canine as a Biomedical Research Model. (M. Shilfrine and F.D. Wilson, eds.) Springfield, Virginia: DOE, Technical Information Center, 1980.
8. **Vriesendorp, H.M.**, and van Bekkum, D.W. Bone Marrow Transplantation in the Canine. p153, In: *The Canine as a Biomedical Research Model* (M. Shilfrine and F.D. Wilson, eds.) Springfield, Virginia: DOE, Technical Information Center, 1980.
9. Heidt, P.J., **Vriesendorp, H.M.**, deGroot, C.W., and Klapwijk, W.M. Selective Decontamination of the Gastrointestinal Tract of Dogs. p209, 7th ICLAS Symposium. Utrecht, 1979. Stuttgart, New York: Gustav Fisher Verlag, 1980.
10. **Vriesendorp, H.M.** The Relative Role of the DLA Complex in Bone Marrow Transplantation. In: *Immunobiology of the major Histocompatibility Complex*. Zaleski MB, Abeyounis CJ, Kano K [eds.] 7th Int. Conv. Immunology. Karger, Basel, Switzerland 1981, pp 214-223
11. Kwaan, H., Rosen, S.T., and **Vriesendorp, H.M.** Blood Transfusion. Chapter 11, in Harry S. Goldsmith Practice of Surgery. Philadelphia, PA.: Harper and Row, 1983.
12. **Vriesendorp, H.M.**, and van Bekkum, D.W. Susceptibility to Total Body Irradiation. In: Broerse, J.J., and MacVittie, T. (eds.) *Response to Total Body Irradiation in Different Species*. Amsterdam: Martinus Nijhoff, pp43-53, 1984.
13. **Vriesendorp, H.M.** Engraftment of Hemopoietic Cells. Chapter 2 in D.W. van Bekkum and B.Lowenberg (eds.) *Bone Marrow Transplantation in Animals and Man. Biological Mechanisms and Clinical Practice*. Marcel Dekker, Inc., 1985.
14. **Vriesendorp, H.M.**, Johnson, P.M., Monroy, R.L., MacVittie, T.J., and van Bekkum, D.W. Influence of Three Interrelated Total Body Irradiation Parameters -Quality, Dose, Nonuniformity on Outcome of Allogeneic Bone Marrow Transplantation in

**Page 18 H. M. VRIESENDORP, M.D., PhD.
4/11/2005**

- Dogs. pp 141-148 in: Progress in Bone Marrow Transplantation. p 141, Galc, R.P. and Champlin, R., (eds.) Alan R. Liss. Inc., New York, 1987.
15. **Vriesendorp, H.M., Quadri, S.M., Williams, J.R.** Radioimmunoglobulin Therapy. Chapter 5, pp84-123. High Dose Cancer Therapy. Pharmacology, Hematopoietins, stem cells. J. O. Armitage, K.H. Antman (eds) Williams & Williams, Baltimore, 1992.
 16. **Quadri, S.M., Vriesendorp H.M.**, Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. The Quarterly Journal of Nuclear Medicine 42: 250-261; 1998.
 17. **Vriesendorp H.M.**, Radiobiology of Cancer Treatment. A Study Guide. Four Chapters: 1. Cancer Problem, 2. Radiation Biology and Cancer, 3. Radiation Therapy Treatment Variables, 4. Radiolabeled Immunoglobulin Therapy. Each chapter is followed by multiple choice questions and calculational problem sets for self evaluation. 250 pages. Can be obtained from author in electronic form.

6 21-05

DATE

This is to acknowledge the receipt of your letter/application dated 4-08-05, and to inform you that the initial processing, which includes an administrative review, has been performed.

There were no administrative omissions. Your application will be assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.


Please provide to this office within 30 days of your receipt of this card:

The action you requested is normally processed within 90 days.

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 470518.
When calling to inquire about this action, please refer to this mail control number.
You may call me at 817-860-8103.

Sincerely,



Licensing Assistant

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)

INFORMATION FROM LTS

: Program Code: 02120
: Status Code: 0
: Fee Category: 7C
: Exp. Date: 20150331
: Fee Comments: CODE 23
: Decom Fin Assur Req'd: N
:

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED BENEFITS HEALTHCARE
Applicant/Licensee: 20050425
Received Date: 3002404
Docket No: 470518
Control No.: 25-12710-01
License No.:
Action Type: Amendment

2. FEE ATTACHED

Amount: _____
Check No.: _____

3. COMMENTS

Signed *Colleen M. ...*
Date 4/29/05

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / __/)

- 1. Fee Category and Amount: _____
- 2. Correct Fee Paid. Application may be processed for:
Amendment _____
Renewal _____
License _____
- 3. OTHER _____

Signed _____
Date _____